Clinical Outcomes of Hydrogel Spacer Injection Space OAR in Men Submitted to Hypofractionated Radiotherapy for Prostate Cancer
| Autor: | Maria Tamburo, Michele Pennisi, Dario Marletta, Francesco Marletta, Pietro Pepe |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Urology General Biochemistry Genetics and Molecular Biology Prostate cancer Seminal vesicle Prostate Median follow-up parasitic diseases medicine Humans Potency Pharmacology business.industry Genitourinary system Prostatic Neoplasms Hydrogels Radiotherapy Dosage Prostate-Specific Antigen medicine.disease Acute toxicity medicine.anatomical_structure Radiation Dose Hypofractionation business Sexual function Research Article |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| Popis: | Background/aim To evaluate the clinical outcomes of men with prostate cancer (PCa) submitted to hydrogel spacer injection before hypofractionated radiotherapy (HRT). Patients and methods From April 2018 to April 2020, 32 patients with clinically localized PCa underwent hydrogel injection Space OAR before HRT to the prostate and seminal vesicle; the prescription dose was 60 Gy in 20 fractions, 5 days/week over 4 weeks. PSA levels, genitourinary (GU) and gastrointestinal (GI) toxicities, and sexual function were prospectively evaluated. Results PSA levels at the median follow up of 15 months was 0.52 ng/ml; 28.1% vs. 78.1% patients had GI vs. GU Grade 0 acute toxicity and 93.7% vs. 0% had GI vs. GU Grade 0 late toxicity. Furthermore, 88.1% of patients kept pretreatment sexual potency. Conclusion The use of the hydrogel Spacer OAR before HRT is useful for reducing acute and late GU and GI toxicities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|